Chinese General Practice ›› 2023, Vol. 26 ›› Issue (36): 4514-4520.DOI: 10.12114/j.issn.1007-9572.2023.0095
Special Issue: 肿瘤最新文章合辑; 消化系统疾病最新文章合辑
• Article • Previous Articles Next Articles
Received:
2023-01-15
Revised:
2023-06-20
Published:
2023-12-20
Online:
2023-07-19
Contact:
ZHU Hong
通讯作者:
朱红
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0095
指标 | 计算公式 |
---|---|
APRI | (AST/ASTULN)×100/PLT |
FIB-4 | (年龄×AST)/PLT×(ALT1/2) |
GPR | GGT/GGTULN×100/PLT |
S-Index | 1 000×GGT/(PLT×ALB2) |
NLR | NE/LY |
PLR | PLT/LY |
FAR | FIB/ALB |
LMR | LY/MO |
NrLR | NE×GGT/LY |
SIRI | MO×NE/LY |
SII | PLT×NE/LY |
PNI | ALB+5×LY |
ALRI | AST/LY |
AAR | AST/ALT |
ANRI | AST/NE |
Table 1 Formulas for the calculation of 15 serologically derived indicators
指标 | 计算公式 |
---|---|
APRI | (AST/ASTULN)×100/PLT |
FIB-4 | (年龄×AST)/PLT×(ALT1/2) |
GPR | GGT/GGTULN×100/PLT |
S-Index | 1 000×GGT/(PLT×ALB2) |
NLR | NE/LY |
PLR | PLT/LY |
FAR | FIB/ALB |
LMR | LY/MO |
NrLR | NE×GGT/LY |
SIRI | MO×NE/LY |
SII | PLT×NE/LY |
PNI | ALB+5×LY |
ALRI | AST/LY |
AAR | AST/ALT |
ANRI | AST/NE |
组别 | 例数 | 性别(男/女) | 年龄≥60岁〔例(%)〕 | 乙肝病史〔例(%)〕 | 肝硬化〔例(%)〕 | AFP>45 ng/mL 〔例(%)〕 | TB>20.5 μmol/L 〔例(%)〕 | ALB<35 g/L 〔例(%)〕 | ALT>40 U/L 〔例(%)〕 | AST>40 U/L 〔例(%)〕 | ALP>125 U/L 〔例(%)〕 |
---|---|---|---|---|---|---|---|---|---|---|---|
MVI阳性 | 108 | 94/14 | 30(27.8) | 94(87.0) | 68(63.0) | 68(63.0) | 29(26.7) | 94(87.0) | 60(55.6) | 67(62.0) | 48(44.4) |
MVI阴性 | 100 | 81/19 | 31(31.0) | 88(88.0) | 71(71.0) | 43(43.0) | 28(28.0) | 86(86.0) | 52(52.0) | 56(56.0) | 30(30.0) |
χ2值 | 1.418 | 0.26 | 0.044 | 1.513 | 8.315 | 0.034 | 0.048 | 0.264 | 0.783 | 4.622 | |
P值 | 0.234 | 0.610 | 0.834 | 0.219 | 0.004 | 0.853 | 0.827 | 0.607 | 0.376 | 0.032 | |
组别 | GGT>50 U/L 〔例(%)〕 | INR>1.185 〔例(%)〕 | PT延长〔例(%)〕 | FIB>3.03 g/L 〔例(%)〕 | WBC> 7.1×109/L 〔例(%)〕 | NE>4.735 ×109/L 〔例(%)〕 | MO>0.545 ×109/L 〔例(%)〕 | PLT> 155.5×109/L 〔例(%)〕 | 肿瘤直径>7.05 cm 〔例(%)〕 | 肿瘤数目>1个〔例(%)〕 | |
MVI阳性 | 82(76.0) | 17(15.7) | 10(9.3) | 67(62.0) | 37(34.2) | 30(27.8) | 30(27.8) | 66(61.1) | 54(50.0) | 34(31.5) | |
MVI阴性 | 69(69.0) | 12(12.0) | 6(6.0) | 50(50.0) | 17(17.0) | 11(11.0) | 17(17.0) | 46(46.0) | 15(15.0) | 16(16.0) | |
χ2值 | 1.252 | 0.606 | 0.777 | 3.057 | 8.047 | 9.235 | 3.448 | 4.771 | 28.692 | 6.815 | |
P值 | 0.263 | 0.436 | 0.378 | 0.080 | 0.005 | 0.002 | 0.063 | 0.029 | <0.001 | 0.009 |
Table 2 Comparison of baseline characteristics of MVI-positive and MVI-negative patients in the model group
组别 | 例数 | 性别(男/女) | 年龄≥60岁〔例(%)〕 | 乙肝病史〔例(%)〕 | 肝硬化〔例(%)〕 | AFP>45 ng/mL 〔例(%)〕 | TB>20.5 μmol/L 〔例(%)〕 | ALB<35 g/L 〔例(%)〕 | ALT>40 U/L 〔例(%)〕 | AST>40 U/L 〔例(%)〕 | ALP>125 U/L 〔例(%)〕 |
---|---|---|---|---|---|---|---|---|---|---|---|
MVI阳性 | 108 | 94/14 | 30(27.8) | 94(87.0) | 68(63.0) | 68(63.0) | 29(26.7) | 94(87.0) | 60(55.6) | 67(62.0) | 48(44.4) |
MVI阴性 | 100 | 81/19 | 31(31.0) | 88(88.0) | 71(71.0) | 43(43.0) | 28(28.0) | 86(86.0) | 52(52.0) | 56(56.0) | 30(30.0) |
χ2值 | 1.418 | 0.26 | 0.044 | 1.513 | 8.315 | 0.034 | 0.048 | 0.264 | 0.783 | 4.622 | |
P值 | 0.234 | 0.610 | 0.834 | 0.219 | 0.004 | 0.853 | 0.827 | 0.607 | 0.376 | 0.032 | |
组别 | GGT>50 U/L 〔例(%)〕 | INR>1.185 〔例(%)〕 | PT延长〔例(%)〕 | FIB>3.03 g/L 〔例(%)〕 | WBC> 7.1×109/L 〔例(%)〕 | NE>4.735 ×109/L 〔例(%)〕 | MO>0.545 ×109/L 〔例(%)〕 | PLT> 155.5×109/L 〔例(%)〕 | 肿瘤直径>7.05 cm 〔例(%)〕 | 肿瘤数目>1个〔例(%)〕 | |
MVI阳性 | 82(76.0) | 17(15.7) | 10(9.3) | 67(62.0) | 37(34.2) | 30(27.8) | 30(27.8) | 66(61.1) | 54(50.0) | 34(31.5) | |
MVI阴性 | 69(69.0) | 12(12.0) | 6(6.0) | 50(50.0) | 17(17.0) | 11(11.0) | 17(17.0) | 46(46.0) | 15(15.0) | 16(16.0) | |
χ2值 | 1.252 | 0.606 | 0.777 | 3.057 | 8.047 | 9.235 | 3.448 | 4.771 | 28.692 | 6.815 | |
P值 | 0.263 | 0.436 | 0.378 | 0.080 | 0.005 | 0.002 | 0.063 | 0.029 | <0.001 | 0.009 |
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
WBC>7.1×109/L | 1.146 | 0.450 | 6.475 | 3.144(1.301,7.598) | 0.011 |
肿瘤直径>7.05 cm | 1.344 | 0.398 | 11.399 | 3.836(1.758,8.372) | 0.001 |
S-Index>0.097 | 1.152 | 0.576 | 4.006 | 3.165(1.024,9.779) | 0.040 |
AAR>0.879 | 0.764 | 0.359 | 4.527 | 2.146(1.062,4.337) | 0.030 |
ANRI>24.074 | 1.018 | 0.437 | 5.422 | 2.769(1.175,6.526) | 0.020 |
Table 3 Multivariate Logistic regression analysis of MVI in patients with HCC
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
WBC>7.1×109/L | 1.146 | 0.450 | 6.475 | 3.144(1.301,7.598) | 0.011 |
肿瘤直径>7.05 cm | 1.344 | 0.398 | 11.399 | 3.836(1.758,8.372) | 0.001 |
S-Index>0.097 | 1.152 | 0.576 | 4.006 | 3.165(1.024,9.779) | 0.040 |
AAR>0.879 | 0.764 | 0.359 | 4.527 | 2.146(1.062,4.337) | 0.030 |
ANRI>24.074 | 1.018 | 0.437 | 5.422 | 2.769(1.175,6.526) | 0.020 |
指标 | 模型组 | 验证组 |
---|---|---|
一致性指数(95%CI) | 0.800(0.739,0.861) | 0.755(0.641,0.868) |
截断值(分) | 174 | 174 |
灵敏度(%) | 90 | 78 |
特异度(%) | 61 | 71 |
阳性预测值(%) | 71 | 76 |
阴性预测值(%) | 85 | 74 |
阳性似然比 | 2.30 | 2.73 |
阴性似然比 | 0.17 | 0.31 |
Table 4 Accuracy of prediction model in predicting MVI
指标 | 模型组 | 验证组 |
---|---|---|
一致性指数(95%CI) | 0.800(0.739,0.861) | 0.755(0.641,0.868) |
截断值(分) | 174 | 174 |
灵敏度(%) | 90 | 78 |
特异度(%) | 61 | 71 |
阳性预测值(%) | 71 | 76 |
阴性预测值(%) | 85 | 74 |
阳性似然比 | 2.30 | 2.73 |
阴性似然比 | 0.17 | 0.31 |
[1] |
|
[2] |
|
[3] |
蔡雪红,陈巍,陈世杰,等. 肝细胞癌术前预测微血管侵犯的研究进展[J]. 中南医学科学杂志,2022,50(3):462-465. DOI:10.15972/j.cnki.43-1509/r.2022.03.040.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
邓家仲,荚卫东. 肝细胞癌微血管侵犯危险因素分析及术前预测列线图模型构建[J]. 中国普通外科杂志,2021,30(7):772-779. DOI:10.7659/j.issn.1005-6947.2021.07.003.
|
[9] |
|
[10] |
|
[11] |
|
[12] |
姚岚清,陈钟. 原发性肝细胞肝癌微血管侵犯的术前预测及其模型的建立[J]. 中国肿瘤外科杂志,2021,13(1):5-11. DOI:10.3969/j.issn.1674-4136.2021.01.002.
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
王丽艳,孔凡刚. 肝病患者血清中AST/ALT比值的临床意义研究[J]. 中西医结合心血管病电子杂志,2020,8(30):97-98. DOI:10.16282/j.cnki.cn11-9336/r.2020.30.074.
|
[19] |
|
[20] |
|
[21] |
邹伟婕,陈立,黄学卿,等. 天冬氨酸转氨酶与中性粒细胞比值对肝癌患者TACE治疗预后的影响[J]. 介入放射学杂志,2017,26(8):705-711. DOI:10.3969/j.issn.1008-794X.2017.08.010.
|
[1] | ZOU Songyan, ZHANG Riyi, LI Xiaodong, MU Yinyu. Analysis of Clinical Characteristics and Risk Factors of Systemic Sclerosis Combined with Sjögren's Syndrome [J]. Chinese General Practice, 2025, 28(06): 737-741. |
[2] | SHI Xiaotian, WANG Shan, YANG Huayu, YANG Yifan, LI Xu, DOU Guoze, MA Qing. A Predictive Nomogram for the Risk of Frailty/Pre-frailty on Inflammatory Biomarkers in the Elderly [J]. Chinese General Practice, 2025, 28(05): 587-593. |
[3] | KONG Linghong, XIE Xiaoxin, FU Yanhua, GAN Lin, YANG Xiaoyan, MA Shujing, LONG Hai. Pre-treatment and Acquired Antiretroviral Drug Resistance among People Living with HIV in Southwest China [J]. Chinese General Practice, 2025, 28(02): 242-249. |
[4] | LIU Mingbo, HE Xinye, YANG Xiaohong, WANG Zengwu. Interpretation of Report on Cardiovascular Health and Diseases in China 2023 [J]. Chinese General Practice, 2025, 28(01): 20-38. |
[5] | TAO Jintao, WU Shouling, ZHAO Xiaohong. Prevalence and Risk Factors of Atrioventricular Block in the Population: a Study Based on the Kailuan Cohort [J]. Chinese General Practice, 2024, 27(36): 4534-4539. |
[6] | GU Shanye, ZHOU Ziyi, CAI Yefeng. Study on Risk Prediction of Non-dementia Vascular Cognitive Impairment in Glycolipid Metabolic Diseases [J]. Chinese General Practice, 2024, 27(35): 4412-4416. |
[7] | ZHANG Bingqing, HU Xinyun, OUYANG Yuqin, XIANG Xinyue, TANG Wenjuan, FENG Wenhuan. Study on Nomogram Prediction Model for Risk Factors of Muscle Mass Loss in Non-obese Patients with Type 2 Diabetes [J]. Chinese General Practice, 2024, 27(33): 4139-4146. |
[8] | Diabetes and Microcirculation Professional Committee of Chinese Society of Microcirculation, Primary Endocrine and Metabolic Diseases Group of the Chinese Society of Endocrinology. Expert Consensus on Screening and Prevention of Diabetic Microvascular Disease for Primary Care (2024) [J]. Chinese General Practice, 2024, 27(32): 3969-3986. |
[9] | XU Yaolong, ZHAO Jiaxin, YANG Ligang. Epidemic Status and Risk Factors of Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2024, 27(30): 3825-3834. |
[10] | QIN Yali, CHEN Jing, LI Jun, WANG Mingdong, OU Weizheng, QIU Jiyao, PENG Yanqing. Construction and Validation of a Predictive Model of Influencing Factors for Fluoroquinolone Resistance in Patients with Pulmonary Tuberculosis: Based on the LASSO-Logistic Regression Model [J]. Chinese General Practice, 2024, 27(30): 3776-3783. |
[11] | REN Lingxuan, LU Ziqi, QI Wei, FENG Zhijie. Functional Analysis of Macrophages in the Progression of Liver Cirrhosis and Liver Cancer [J]. Chinese General Practice, 2024, 27(29): 3654-3663. |
[12] | FU Wei, CHENG Guobin, LYU Linya, DING Yao, WANG Yao, ZHAO Junlong. Association of Monounsaturated Fatty Acid Intake with Nonalcoholic Fatty Liver Disease Risk in Chinese Han Adults: a Retrospective Case-control Study [J]. Chinese General Practice, 2024, 27(29): 3623-3628. |
[13] | LI Qiuling, TANG Wenwu, YU Yiwen, DENG Huan, YANG Xiaohua, CHEN Xiaoxia, JI Yifei. Establishment and Verification of Risk Prediction Model for Silent Brain Infarction in Maintenance Hemodialysis Patients: a Multicenter Study [J]. Chinese General Practice, 2024, 27(26): 3232-3239. |
[14] | ZHU Yaming, DU Li, WANG Huanhui, WANG Peipei. Obstructive Sleep Apnea-hypopnea Syndrome and Severe Asthma: Advances and Challenges [J]. Chinese General Practice, 2024, 27(25): 3192-3196. |
[15] | LI Hongji, ZHAO Xiaolong, HU Wei, HAN Donghui, WANG Anhui, QIN Weijun. Development and Validation of a Prediction Model for Prostate Cancer Early Screening [J]. Chinese General Practice, 2024, 27(20): 2483-2490. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||